Related Experiment Videos
Nurse prescribing in glaucoma.
Z K Johnson1, P G Griffiths, M K Birch
1Department of Ophthamology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Eye (London, England)
|February 13, 2003
Summary
Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
A Supranuclear Disorder of Ocular Motility as a Rare Initial Presentation of Motor Neurone Disease.
Neuro-ophthalmology (Aeolus Press)·2016
Same author
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England.
American journal of human genetics·2016
Same author
Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy.
Brain : a journal of neurology·2013
Same author
Subclinical multisystem neurologic disease in "pure" OPA1 autosomal dominant optic atrophy.
Neurology·2011
Same author
Pattern of retinal ganglion cell loss in dominant optic atrophy due to OPA1 mutations.
Eye (London, England)·2011
Same author
Eye movement recordings to investigate a supranuclear component in chronic progressive external ophthalmoplegia: a cross-sectional study.
The British journal of ophthalmology·2010
Same journal
Determinants of regression kinetics in observed stage 3 retinopathy of prematurity without plus disease.
Eye (London, England)·2026
Same journal
Oculomics and the NHS: A UK opportunity to translate eye-derived biomarkers into population health.
Eye (London, England)·2026
Same journal
Long-term follow-up and outcomes of a Diabetic Eye Screening Programme in patients aged 80 with no diabetic eye disease at baseline: should we be routinely screening this cohort?
Eye (London, England)·2026
Same journal
Real world experience with faricimab in switched neovascular AMD and evaluation of reloading versus interval matching regimes.
Eye (London, England)·2026
Same journal
"When the lens drew a continent: a cartographic clue to Alport syndrome".
Eye (London, England)·2026
Same journal
Infographic: efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity.
Eye (London, England)·2026